Across these AAIC presentations, we are showing how AC Immune’s Morphomer®-based small molecule appr

AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC ® 2026 Lau

AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeu

AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer

AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeu

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's D

AC Immune (ACIU) witnesses a hammer chart pattern, indicating support found by the stock after losin

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patie

Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contri

AC Immune (ACIU) appears to have found support after losing some value lately, as indicated by the f

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM Co-founder and CEO, Dr Andre

AC Immune (ACIU) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estima

AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial o

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherap

Dow futures down 0.1%. FGI Industries (NASDAQ: FGI) reported mixed results for Q4, with losses of 29

AC Immune stock gains after expansion of its agreement with LLY, adding next-generation Tau Morphome

Here is how AC Immune (ACIU) and Assertio (ASRT) have performed compared to their sector so far this

This will help fund the biotech's development of a unique treatment for neurodegenerative diseases l

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly Amen

AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflec

Here is how AC Immune (ACIU) and Anavex Life Sciences (AVXL) have performed compared to their sector

AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update Phase 2 interim r

AC Immune (NASDAQ: ACIU - Get Free Report) and Sagimet Biosciences (NASDAQ: SGMT - Get Free Report)

AC Immune receives a "Buy" rating, driven by positive phase 2 VacSYn trial results for ACI-7104.056

  During Thursday, 849 stocks hit new 52-week lows.

Stocks That Hit 52-Week Lows On Monday